Insight Molecular Diagnostics Inc (IMDX)

NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-10-23

$2.83-0.35%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Insight Molecular Diagnostics Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	467,280
EPS	—	-0.234
Annual ending 2026-12-31
Revenue	—	969,000
EPS	—	-0.905
Annual ending 2027-12-31
Revenue	—	6.67M
EPS	—	-0.861

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Reduce cash burn to $6 million per quarter	Management aims to reduce cash burn to $6 million per quarter by late 2026.	Under Pressure	cash burn remains above $6M per quarter in 2H 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Progress on strategic agreements with Quest Diagnostics	Insight Molecular Diagnostics has a key agreement with Quest Diagnostics supporting growth.	Improving	agreement is terminated or materially reduced	Qualitative: Specimen Collection Agreement with Quest Diagnostics active (May 2026) May 2026 filing confirms active Specimen Collection Agreement with Quest Diagnostics. No subsequent news reports termination or reduction. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue growth stabilizes or improves	A primary condition in Insight Molecular Diagnostics Inc's published investment case. The stated target is revenue decline less than -20% YoY.	Broken	revenue decline exceeds -20% YoY in FY27	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue$0.01B

Unavailable → $0.01B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	2 / 4
2026-07-25	Unavailable	Unavailable	2 / 4
2026-07-26	Unavailable	Unavailable	2 / 4
2026-07-27	Unavailable	Unavailable	1 / 4
2026-07-28	Unavailable	Unavailable	2 / 4
2026-07-29	Unavailable	Unavailable	1 / 4
2026-07-30	Unavailable	Unavailable	1 / 4
2026-07-31	Unavailable	Unavailable	1 / 4
2026-08-01	Unavailable	Unavailable	2 / 4
2026-08-02	Unavailable	Unavailable	1 / 4
2026-08-03	Unavailable	Unavailable	1 / 4
2026-08-04	Unavailable	Unavailable	1 / 4
2026-08-05	Unavailable	Unavailable	1 / 4
2026-08-06	Unavailable	Unavailable	1 / 4
2026-08-07	Unavailable	Unavailable	2 / 4
2026-08-08	Unavailable	Unavailable	1 / 4
2026-08-09	Unavailable	Unavailable	1 / 4
2026-08-10	Unavailable	Unavailable	1 / 4
2026-08-12	Unavailable	Unavailable	1 / 3
2026-08-13	Unavailable	Unavailable	2 / 4
2026-08-14	Unavailable	Unavailable	2 / 4
2026-08-15	Unavailable	Unavailable	2 / 3
2026-08-16	Unavailable	Unavailable	2 / 3
2026-08-17	Unavailable	Unavailable	2 / 3
2026-08-18	Unavailable	Unavailable	2 / 3
2026-08-19	Unavailable	Unavailable	2 / 4
2026-08-20	Unavailable	Unavailable	2 / 4
2026-08-21	Unavailable	Unavailable	2 / 4
2026-08-22	Unavailable	Unavailable	2 / 4
2026-08-23	Unavailable	Unavailable	2 / 4
2026-08-24	Unavailable	Unavailable	2 / 4
2026-08-25	Unavailable	$6,706,600	3 / 5
2026-08-26	Unavailable	$6,706,600	3 / 5
2026-08-27	Unavailable	$6,706,600	3 / 5
2026-08-28	Unavailable	$6,706,600	3 / 5
2026-08-29	Unavailable	$6,706,600	3 / 5
2026-08-30	Unavailable	$6,706,600	3 / 5
2026-08-31	Unavailable	$6,706,600	3 / 5
2026-09-01	Unavailable	$6,706,600	3 / 5
2026-09-02	Unavailable	$6,706,600	3 / 5
2026-09-03	Unavailable	$6,706,600	3 / 5
2026-09-04	Unavailable	$6,706,600	3 / 5
2026-09-05	Unavailable	$6,706,600	3 / 5
2026-09-06	Unavailable	$6,706,600	3 / 5
2026-09-07	Unavailable	$6,706,600	3 / 5
2026-09-08	Unavailable	$6,706,600	3 / 5
2026-09-09	Unavailable	$6,706,600	3 / 5
2026-09-10	Unavailable	$6,706,600	3 / 5
2026-09-11	Unavailable	$6,706,600	3 / 5
2026-09-12	Unavailable	$6,706,600	3 / 5
2026-09-13	Unavailable	$6,706,600	3 / 5
2026-09-14	Unavailable	$6,706,600	3 / 5
2026-09-15	Unavailable	$6,706,600	3 / 5
2026-09-16	Unavailable	$6,706,600	3 / 5
2026-09-17	Unavailable	$6,706,600	3 / 5
2026-09-18	Unavailable	$6,706,600	3 / 5
2026-09-19	Unavailable	$6,706,600	3 / 5
2026-09-20	Unavailable	$6,706,600	3 / 5
2026-09-21	Unavailable	$6,706,600	3 / 5
2026-09-22	Unavailable	$6,706,600	3 / 5
2026-09-23	Unavailable	$6,666,600	3 / 5
2026-09-24	Unavailable	$6,666,600	3 / 5
2026-09-25	Unavailable	$6,666,600	3 / 5
2026-09-26	Unavailable	$6,666,600	3 / 5
2026-09-27	Unavailable	$6,666,600	3 / 5
2026-09-28	Unavailable	$6,666,600	3 / 5
2026-09-29	Unavailable	$6,666,600	3 / 5
2026-09-30	Unavailable	$6,666,600	3 / 5
2026-10-01	Unavailable	$6,666,600	3 / 5
2026-10-02	Unavailable	$6,666,600	3 / 5
2026-10-03	Unavailable	$6,666,600	3 / 5
2026-10-04	Unavailable	$6,666,600	3 / 5
2026-10-05	Unavailable	$6,666,600	3 / 5
2026-10-06	Unavailable	$6,666,600	3 / 5
2026-10-07	Unavailable	$6,666,600	3 / 5
2026-10-08	Unavailable	$6,666,600	3 / 5
2026-10-09	Unavailable	$6,666,600	3 / 5
2026-10-10	Unavailable	$6,666,600	3 / 5
2026-10-11	Unavailable	$6,666,600	3 / 5
2026-10-12	Unavailable	$6,666,600	3 / 5
2026-10-13	Unavailable	$6,666,600	3 / 5
2026-10-14	Unavailable	$6,668,860	3 / 5
2026-10-15	Unavailable	$6,668,860	3 / 5
2026-10-16	Unavailable	$6,668,860	3 / 5
2026-10-17	Unavailable	$6,668,860	3 / 5
2026-10-18	Unavailable	$6,668,860	3 / 5
2026-10-19	Unavailable	$6,668,860	3 / 5
2026-10-20	Unavailable	$6,668,860	3 / 5
2026-10-21	Unavailable	$6,668,860	3 / 5
2026-10-22	Unavailable	$6,668,860	3 / 5
2026-10-23	Unavailable	$6,668,860	3 / 5
2026-10-24	Unavailable	$6,668,860	3 / 5

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	2	2
2026-06-01	2	2
2026-07-01	2	2
2026-08-01	3	2
2026-09-01	3	2
2026-10-01	3	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 3 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Reduce cash burn to $6 million per quarterPublished status: Under Pressure
Revenue growth stabilizes or improvesPublished status: Broken

Next proof point

Nov 9, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.9%Typical daily move · historical

Downside history

-69.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Insight Molecular Diagnostics Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative growth business, not an established earnings compounder, because it remains loss-making and depends on expanding a product that is still awaiting FDA marketing authorization. The long-term thesis is intact, but execution and cash use remain important concerns.

What's priced into Insight Molecular Diagnostics Inc

IMDX is valued at a premium to peers, with the valuation case relying on future opportunity rather than current earnings. The expectations gap suggests the market may not fully reflect the company’s weak results and execution risks, though confidence in that assessment is low.

What the fundamentals likely do

Near term, revenue is likely to remain limited while commercial product sales await FDA authorization; recent revenue was modest, and cash burn was above management’s stated average target. Management continues to prioritize authorization, commercialization, and lower cash burn, but progress so far is mixed, and erratic earnings create risk around the next report.

What Insight Molecular Diagnostics Inc hinges on

Over the next year, the key swing factor is whether FDA authorization arrives as management expects and leads to broader commercial adoption. Near term, a guidance cut or further weakening in jobs data could pressure the business outlook, while stronger results and guidance from healthcare peers would support the sector backdrop.